441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Reports Business Updates and First Quarter 2026 Financial Results
Annual Report to Security Holders
Other Events
Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results
Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)
Shareholder votes
Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results
Ovid's OV329 Shows Strong Inhibitory Activity & Best-in-Category Safety
Q1
FY 2025
Q3
Q2
Amended Annual Report
FY 2024
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
PREM14A
Correspondence
Submission Upload
S-8 POS